Faglig rapport 2005 - Helse Vest

Curr Drug Targets. 2005;6(6):631-46PMID: 161787975 forskningspublikasjoner (inkl. abstracts) er publisert i 2005:Ånensen N, Skavland J, Stapnes C, Ryningen A, Gjertsen BT, and Bruserud Ø"Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-transretinoic acid: A case report."Leukemia, in press. 2006Stapnes C, Ryningen A, Gjertsen BT, Bruserud Ø"Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused an early increase inreticulated plateles and a later persisting increase of peripheral blood plateles for a patient with acute myelogenous leukemia."Leukemia Res., in press. 2006Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT"Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in AML"Expert Opin. Ther. Targets (2006) 10(1) in press. ReviewGjesteredaktør Ø Bruserud: Forfattere vil inkludere samarbeidspartnere ved Helse bergen og UiB, i tillegg til utenlandskeforfattere."RNA AS A TOOL AND A TARGET IN CANCER THERAPY"CURRENT PHARMACEUTICAL BIOTECHNOLOGY. SPECIAL ISSUE DEDICATED RNA . 2006-2007 (blir til som følge av støtte viaSenter for translasjonell forskning)Gjertsen BT"Individualizing therapy in acute myeloid leukemia through modulation of signaling networks"Onkologisk forum, Tromsø, 18. November. Foredrag267